In a report on Moderna’s manufacturing advances and why cross-tumour data still lag expectations, the analysis concludes that the analyst day supplied useful operational detail on intismeran but did not shift its view that expectations have moved ahead of the evidence. The central argument is that manufacturing progress answers an execution question, not the larger efficacy question that will ultimately determine the platform’s value.
Continue Reading
This article is for pass holders.
30-Day Pass$12.00One-time purchase · no auto-renewalBuy 30 DaysSave $24.00
365-Day Pass$120.00
Already a pass holder? Sign in · Continue with Google